Celecoxib is often combined with cytochrome P450 2D6 substrates in general clinical practice.
Molden
Espen
E
Braathen
Pia
P
D000639:Amitriptyline / Q000627:therapeutic use; D000068579:Celecoxib; D003061:Codeine / Q000627:therapeutic use; D003195:Computer Communication Networks; D019389:Cytochrome P-450 CYP2D6 / Q000627:therapeutic use; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004334:Drug Administration Schedule; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D004512:Education, Pharmacy / Q000379:methods; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D009664:Norway / Q000453:epidemiology; D010593:Pharmaceutical Services / Q000639:trends; D010595:Pharmacists; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data / Q000639:trends; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D013997:Time Factors
D065690:Cytochrome P-450 CYP2D6 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000639:Amitriptyline; D019389:Cytochrome P-450 CYP2D6; D008790:Metoprolol; D000068579:Celecoxib; D003061:Codeine